Photo by gratisography.com
The Lilly Clinical Open Innovation (LCOI) blog, like much of the work we do in innovation, started as a thoughtful experiment. We believed that a blog would provide a great opportunity to openly explore clinical innovation topics and drive discussions around improving the patient experience. So in March of 2012, we launched the LCOI blog with the publication of our first post.
What was initially an experiment has turned into a wonderful and rewarding success! Since that first blog post over three years ago, we’ve published over 210 additional posts, while continuing to learn and evolve along the way. We’ve had many fantastic discussions with you, our audience, about how to improve the clinical trial experience for patients, meanwhile speeding innovation and scientific discovery. And we’re just getting started.
Hello, dear blog followers! Given your wonderful support of Lilly Clinical Open Innovation (LCOI), we wanted you to be the first to know that our blog is moving. More details about our move will be shared in a forthcoming blog post, but in the meantime, we’d like to share some highlights with you.
Next week the LCOI blog will be moved over to LillyPad, Lilly’s corporate blog. You will be able to find all of our posts, past and future, in LillyPad’s new Clinical Innovation section. Our Twitter handle will remain the same. As a blog subscriber, you should also know that you will no longer have the ability to subscribe to blogs via email, though we are looking to add that capability. To make sure that you are notified as new posts are published, we recommend that you subscribe to our RSS feed.
Thank you so much for the support you have shown LCOI. We look forward to expanding the conversation with you as we move to a new platform and begin this new chapter. See you next week at our new home!
Imagine for a moment you are a patient considering clinical trial participation. Or perhaps you really are considering clinical trial participation (good for you)! Either way, let’s say you want to understand more about informed consent in clinical trials. If you are like most patients today, you’ll look to a search engine for answers. So go ahead and do that. Head to your favorite search engine and type “informed consent clinical trials.” I’ll wait right here for you to return.
What did you find in the search results?
Here is what we noticed. First, patients have to filter through a lot of information to find what they need. They might find regulatory documents intended for research professionals mixed in with introductory content about informed consent. Second, the introductory content available is primarily static text. This static text is helpful, but it’s not as rich or engaging as it would be if accompanied by visual or interactive media. In short, it’s not easy for patients to educate themselves about informed consent in clinical trials.
Click the image to view the interactive infographic.
2011 Diversity Conference by Oregon Department of Transportation is licensed under CC by 2.0
Failing to recruit a diverse population of patients for clinical trials can have a negative impact on drug research. Last year, Lilly CEO John Lechleiter pointed out in a Forbes editorial that “when clinical trials are skewed toward Caucasians, researchers can miss key interactions between the drug and genes.” It’s unfortunate to think that we may be missing opportunities to create more effective treatments due to these gaps in knowledge and understanding.
National Minority Health Month and National Minority Cancer Awareness Week, observed each year in April, were created to address the issues preventing minorities from having full access to healthcare options. Among the many health-related disparities that minorities face are fewer opportunities to learn about and enroll in clinical research studies. This disparity is most pronounced in the area of cancer.